About Immuneering Corp
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://immuneering.com/
Frequently Asked Questions
What is the 52-week range for IMRX?
The 52-week high is $8.48 and the 52-week low is $3.86.
What is the P/E ratio for IMRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for IMRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -27.15%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -9610.00%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.94.
Analyst Recommendation Trends
Wall Street analyst consensus for IMRX over the last few months:
Latest IMRX News
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
- Atebimetinib enhances PD-1 checkpoint blockade in preclinical models of RAS mutant tumors - - Findings provide additional mechanistic rationale for upcoming Phase 2 study of atebimetinib in combination with PD-1 blockade in lung cancer patients - NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a poster will be presented at the 41st An
Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib’s Mechanisms Designed to Extend Survival in Pancreatic Cancer
- Stable or increased weight was twice as common among pancreatic cancer patients in the atebimetinib + mGnP study, compared to those in a benchmark study - - Patients with stable or increased weight at three months had significantly longer overall survival than patients who lost weight at three months - - Overall survival was comparable among patients with moderate and deeper tumor volume reductions, suggesting presence of tumor reduction may be more important than depth of response - - Finding
Immuneering to Present at the ESMO Congress 2026
- Trial in progress poster will highlight the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib + mGnP in first-line pancreatic cancer patients -NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that a trial in progress abstract featuring the ongoing Phase 3 MAPKeeper 301 trial of atebimetinib in combination with modified gemcitabine/nab-pa
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
- Expands on previously reported findings in which 84% of evaluable first-line PDAC patients treated with atebimetinib + mGnP maintained or gained weight at three months - - New analyses evaluate the overall survival implications of both preserving body mass and reducing tumor volume - NEW YORK, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will
Immuneering To Present Data At American Association For Cancer Research Conference On Pancreatic Cancer: New Frontiers In Biology And Therapeutic Development
Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced it will present a poster at the American Association for
Immuneering to Participate in Upcoming Investor Conferences
NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management plans to participate in the following upcoming investor conferences: Cantor Global Healthcare Conference (September 9-11 in New York City) Format: Fireside Chat and 1x1 Investor MeetingsDate/Time: Thursday, September 10, 2026, from 2:45-3:15 pm ET H.C. Wainwright 28th Annual Gl
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-16 | Gengos Andrew | +650,000 | - | - |
| 2026-06-23 | Zeskind Benjamin J. | +2,400 | $4.5617 | $10,948 |
| 2026-06-15 | Hall Brett Matthew | +6,035 | $4.15 | $25,045 |
| 2026-06-11 | Feinberg Peter | +33,350 | - | - |
| 2026-06-11 | KEATING LAURIE | +33,350 | - | - |
| 2026-06-11 | HAUSMAN DIANA | +33,350 | - | - |
| 2026-06-11 | Schall Thomas J. | +33,350 | - | - |
| 2026-06-11 | CARPENTER ROBERT J | +33,350 | - | - |
| 2026-03-13 | Neufeld Leah R | +3,628 | $4.2925 | $15,573 |
| 2026-02-03 | Bookman Michael | +176,000 | - | - |
| 2026-02-03 | Brakewood Harold Eugene | +140,000 | - | - |
| 2026-02-03 | Hall Brett Matthew | +344,000 | - | - |
| 2026-02-03 | Morales Mallory | +140,000 | - | - |
| 2026-02-03 | Neufeld Leah R | +140,000 | - | - |
| 2026-02-03 | Zeskind Benjamin J. | +688,000 | - | - |
| 2026-02-03 | Matushansky Igor | +140,000 | - | - |
| 2026-01-16 | Brakewood Harold Eugene | +5,250 | $4.76 | $24,990 |
| 2026-01-15 | Schall Thomas J. | +21,645 | $4.6681 | $101,041 |
| 2026-01-15 | Hall Brett Matthew | +2,298 | $4.57 | $10,502 |
| 2026-01-13 | Neufeld Leah R | +2,626 | $4.153 | $10,906 |
| 2026-01-12 | Feinberg Peter | +20,000 | $4.3452 | $86,904 |
| 2026-01-01 | Feinberg Peter | +7,888 | - | - |
| 2026-01-01 | KEATING LAURIE | +7,888 | - | - |
| 2025-10-03 | Feinberg Peter | +7,500 | $6.67 | $50,025 |